Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.5.0.2
Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
6 Months Ended
Jun. 30, 2016
Evofosfamide | Collaborative Arrangement Product Agreement | Merck KGaA  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]  
Percentage share of eligible worldwide development expenses 70.00%